Jump to content

2CBFly-NBOMe: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Adding category Category:Amines (using HotCat)
No edit summary
Line 20: Line 20:
}}
}}


'''2CBFly-NBOMe''' ('''NBOMe-2C-B-FLY''') is a compound indirectly derived from the [[phenethylamine]] [[psychedelic|hallucinogen]] [[2C-B]], and related to benzodifurans like [[2C-B-FLY]] and N-benzylphenethylamines like [[NBOMe-2C-I]]. It was discovered in 2004 by Ralf Heim at the [[Free University of Berlin]],<ref>[http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 Ralf Heim PhD. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. (German)]</ref> and subsequently investigated in more detail by a team at [[Purdue University]] led by [[David Nichols]].<ref>[http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.]</ref> It acts as a potent [[partial agonist]] for the [[5HT2A receptor|5HT<sub>2A</sub>]] [[serotonin]] [[Receptor (biochemistry)|receptor]] subtype, with a [[Dissociation constant|Ki]] of 0.14nM at the rat 5HT<sub>2A</sub> receptor.
'''2CBFly-NBOMe''' ('''NBOMe-2C-B-FLY''') is a compound indirectly derived from the [[phenethylamine]] [[psychedelic|hallucinogen]] [[2C-B]], and related to benzodifurans like [[2C-B-FLY]] and N-benzylphenethylamines like [[NBOMe-2C-I]]. It was discovered in 2002,<ref>Elz S, Kläß T, Warnke U, Pertz HH. Development of highly potent partial agonists and chiral antagonists as tool for the study of 5-HT2A-receptor mediated function. ''Naunyn-Schmiedeberg's Archives of Pharmacology''. 2002;365:R29.</ref> and further researched by Ralf Heim at the [[Free University of Berlin]],<ref>[http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 Ralf Heim PhD. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. (German)]</ref> and subsequently investigated in more detail by a team at [[Purdue University]] led by [[David Nichols]].<ref>[http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.]</ref> It acts as a potent [[partial agonist]] for the [[5HT2A receptor|5HT<sub>2A</sub>]] [[serotonin]] [[Receptor (biochemistry)|receptor]] subtype, with a [[Dissociation constant|Ki]] of 0.14nM at the rat 5HT<sub>2A</sub> receptor.


{{pharm-stub}}
{{pharm-stub}}

Revision as of 09:05, 4 June 2010

2CBFly-NBOMe
Identifiers
  • N-(2-methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b’]difuran-4-yl)-2-aminoethane
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H22BrNO3
Molar mass404.297 g/mol g·mol−1
3D model (JSmol)
  • c24CCOc4c(Br)c1CCOc1c2CCNCc3ccccc3OC

2CBFly-NBOMe (NBOMe-2C-B-FLY) is a compound indirectly derived from the phenethylamine hallucinogen 2C-B, and related to benzodifurans like 2C-B-FLY and N-benzylphenethylamines like NBOMe-2C-I. It was discovered in 2002,[1] and further researched by Ralf Heim at the Free University of Berlin,[2] and subsequently investigated in more detail by a team at Purdue University led by David Nichols.[3] It acts as a potent partial agonist for the 5HT2A serotonin receptor subtype, with a Ki of 0.14nM at the rat 5HT2A receptor.

Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

See also

References

  1. ^ Elz S, Kläß T, Warnke U, Pertz HH. Development of highly potent partial agonists and chiral antagonists as tool for the study of 5-HT2A-receptor mediated function. Naunyn-Schmiedeberg's Archives of Pharmacology. 2002;365:R29.
  2. ^ Ralf Heim PhD. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. (German)
  3. ^ Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=2CBFly-NBOMe&oldid=365987523"